A first-in-human trial evaluating an experimental treatment for Ebola virus disease has begun at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. The Phase 1 clinical trial is examining the safety and tolerability of a single monoclonal antibody called mAb114, which was developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, and their collaborators. Investigators aim to enroll between 18 and 30 healthy volunteers aged 18 to 60. The trial will not expose participants to Ebola virus.
All news from R&D
A new study shows that a kind of E. coli most associated with "travelers' diarrhea" and children in underdeveloped areas of the world causes more severe disease in people with blood type A. The study is published in The Journal of Clinical Investigation
In a mouse study, a drug that has helped millions of people around the world manage their diabetes might also help people ready to kick their nicotine habits.
The researchers found that the two molecules could replicate the benefits of exercise which could lead to better athletic performance, improved mobility in the elderly and the prevention of aging-associated diseases.
New research had shown that a diet high in fat and cholesterol could deplete the rate of artery-protecting immune cells, turning them into promoters of inflammation, which exacerbate atherosclerotic plaque formation.
VCU Massey Cancer Center has identified two genes that might be responsible for the replication of the Epstein-Barr virus, an infection that drives the growth of several types of cancer. The discovery could lead to the novel therapies for cancer.
Chimeric antigen receptor T-cell therapy has produced some dramatic responses in pediatric acute lymphoblastic leukemia, but the responses have been less spectacular in other hematologic malignancies, and they have been disappointing in solid tumors.
Four new polyhydroxy steroidal glycosides; culcinosides A–D (1, 2, 4, and 7), along with three known compounds; echinasteroside C (3), linckoside F (5), and linckoside L3 (6) were isolated from the ethanol extract of starfish Culcita novaeguineae.
A prison, in Tokushima, 520 km west of Tokyo, a building to house elderly inmates, putting itself at the forefront of an effort to cope with Japan's gregarious prisoner population. The number of prisoners aged 60 or older has risen 7% from a decade ago to 9,308.
The study was designed to make tumor cells more immunogenic such that unmodified gamma delta T cells respond aggressively to the genetically-modified tumor cells as well as tumor cells at sites distant to the treated area.
A new study had identified a direct cooperation between two cancer genes which paves the way for targeted treatments, not only in Acute lymphoblastic leukemia but also in other leukemias where JAK3/STAT5 could have cooperated with HOXA9.